Alpha Therapeutic Corp., of Los Angeles, named James Pennington senior vice president, research, development and clinical affairs.
Biogen Inc., of Cambridge, Mass., appointed Thomas Bucknum vice president-general counsel and secretary.
Biomerica Inc., of Newport Beach, Calif., elected to its board of directors Francis Cano, former president and chief operating officer of Aviron, of Mountain View, Calif.
BioStar Inc., of Boulder, Colo., named Noel Doheny president and CEO.
Bio-Technology General Corp., of Iselin, N.J., promoted Robert Shaw to senior vice president.
Biovector Therapeutics SA, of Toulouse, France, appointed to its board of directors Georges Hibon, former president and CEO of Pasteur Merieux Connaught of North America.
Celgene Corp., of Warren, N.J., named Robert Hugin chief financial officer and senior vice president.
Cellegy Pharmaceuticals Inc., of South San Francisco, appointed John Dietrich vice president, research and development.
Chiron Corp., of Emeryville, Calif., named Paul Hastings president of its biopharmaceuticals business.
Coelacanth Corp., of East Windsor, N.J., named John Skolas chief financial officer and Barry Wolitzky vice president of discovery.
COR Therapeutics Inc., of South San Francisco, promoted Todd Lorenz to vice president, medical affairs.
Cortex Pharmaceuticals Inc., of Irvine, Calif., named Ursula Staubli vice president of biological research.
CpG ImmunoPharmaceuticals Inc., named Ralph Venhaus vice president of medical affairs.
Cubist Pharmaceuticals Inc., of Cambridge, Mass., appointed to its board of directors Walter Maupay, former group executive and president of Calgon Vestal Laboratories; Trudie Resch, an investment manager with Sofinov Society Financiere D'Innovation Inc., of Montreal; and John Zabriskie, chief executive officer of NEN Life Science Products Inc.